Patents by Inventor Carol Toth
Carol Toth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100168029Abstract: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.Type: ApplicationFiled: March 10, 2010Publication date: July 1, 2010Inventors: John C. Lee, Carol A. Toth
-
Patent number: 7390498Abstract: A porous ?-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 ?m, preferably 50-125 ?m. The porous ?-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous ?-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous ?-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous ?-TCP material and inducing bone formation are also provided.Type: GrantFiled: March 29, 2005Date of Patent: June 24, 2008Assignee: Stryker CorporationInventors: Paresh S Dalal, Godofredo R Dimaano, Carol A Toth, Shailesh C Kulkarni
-
Patent number: 7357941Abstract: A porous ?-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 ?m, preferably 50-125 ?m. The porous ?-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous ?-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous ?-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous ?-TCP material and inducing bone formation are also provided.Type: GrantFiled: March 29, 2005Date of Patent: April 15, 2008Assignee: Stryker CorporationInventors: Paresh S Dalal, Godofredo R Dimaano, Carol A Toth, Shailesh C Kulkarni
-
Publication number: 20070196342Abstract: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to, the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about 4 and about 8. The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.Type: ApplicationFiled: December 13, 2006Publication date: August 23, 2007Inventors: Khalid Sadozai, Carol Toth
-
Publication number: 20060292198Abstract: A porous ?-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 ?m, preferably 50-125 ?m. The porous ?-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous ?-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous ?-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous ?-TCP material and inducing bone formation are also provided.Type: ApplicationFiled: March 29, 2005Publication date: December 28, 2006Inventors: Paresh Dalal, Godofredo Dimaano, Carol Toth, Shailesh Kulkarni
-
Publication number: 20050170012Abstract: A porous ?-tricalcium phosphate material for bone implantation is provided. The multiple pores in the porous TCP body are separate discrete voids and are not interconnected. The pore size diameter is in the range of 20-500 ?m, preferably 50-125 ?m. The porous ?-TCP material provides a carrier matrix for bioactive agents and can form a moldable putty composition upon the addition of a binder. Preferably, the bioactive agent is encapsulated in a biodegradable agent. The invention provides a kit and an implant device comprising the porous ?-TCP, and a bioactive agent and a binder. The invention also provides an implantable prosthetic device comprising a prosthetic implant having a surface region, a porous ?-TCP material disposed on the surface region and optionally comprising at least a bioactive agent or a binder. Methods of producing the porous ?-TCP material and inducing bone formation are also provided.Type: ApplicationFiled: March 29, 2005Publication date: August 4, 2005Inventors: Paresh Dalal, Godofredo Dimaano, Carol Toth, Shailesh Kulkarni
-
Patent number: 6193979Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intercellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: May 25, 1995Date of Patent: February 27, 2001Assignee: Avant Immunotherapeutics, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 6169068Abstract: A method is disclosed for treating diseases or disorders involving complement by pulmonary administration of complement inhibitory proteins such as soluble complement receptor type 1 (sCR1). The present invention relates to the direct treatment of certain complement related disorders by administering complement inhibitory proteins via the pulmonary route, in particular, by direct delivery to the lungs by aerosolization of a complement inhibitory protein and subsequent inhalation.Type: GrantFiled: August 11, 1995Date of Patent: January 2, 2001Assignees: Avant Immunotherpeutics, Inc., Regents of the University of MinnesotaInventors: James L. Levin, Jean F. Regal, Carol A. Toth
-
Patent number: 5976540Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: April 16, 1998Date of Patent: November 2, 1999Assignee: T Cell Sciences, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 5856300Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type I, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Louis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: November 13, 1995Date of Patent: January 5, 1999Assignee: T Cell Sciences, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 5281697Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 20 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO:4. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.Type: GrantFiled: May 31, 1991Date of Patent: January 25, 1994Assignees: Applied Biotechnology, Inc., New England Deacons Hospital Corp.Inventors: Carol A. Toth, Peter Thomas, Sibusisiwe M. Maswoswe, Joseph V. Briggman
-
Patent number: 5278290Abstract: Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 21 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO: 2. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.Type: GrantFiled: May 31, 1991Date of Patent: January 11, 1994Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital, Corp.Inventors: Peter Thomas, Carol A. Toth, Sibusisiwe M. Maswoswe, Joseph V. Briggman
-
Patent number: 5245017Abstract: Disclosed are methods of isolating a protein which binds carcinoembryonic antigen. These methods include the following steps. A biological sample containing carcinoembryonic antigen (CEA) and a CEA-binding protein (CBP) is provided and contacted with a divalent cation at a concentration and for a time sufficient to allow the binding of the CBP to CEA, thereby forming a CBP-CEA conjugate. The sample is then contacted with an adsorbent that binds CEA for a time sufficient to allow adsorbance to the adsorbent. Portions of the sample not adsorbed are removed. The CBP is then disassociated from the conjugate and is collected.Type: GrantFiled: May 31, 1991Date of Patent: September 14, 1993Assignees: Applied Biotechnology, Inc., New England Deaconess Hospital CorporationInventors: Sibusisiwe M. Maswoswe, Joseph V. Briggman, Carol A. Toth, Peter Thomas
-
Patent number: 5241052Abstract: Disclosed is carcinoma orosomucoid-related antigen (CORA), a glycoprotein which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and is characterized by having a molecular weight of about 46,000-50,000 daltons on SDS-polyacrylamide gels, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, an amino acid sequence defined in the Sequence Listing by SEQ ID NO:1, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed is a method for detecting and monitoring carcinoma.Type: GrantFiled: December 19, 1990Date of Patent: August 31, 1993Assignee: New England Deaconess Hospital CorporationInventors: Carol A. Toth, Peter Thomas
-
Patent number: 5204450Abstract: Disclosed is a glycoprotein, CORA, which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characterized by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.Type: GrantFiled: January 9, 1990Date of Patent: April 20, 1993Assignee: New England Deaconess Hospital CorporationInventors: Carol A. Toth, Peter Thomas
-
Patent number: 4914021Abstract: Disclosed is a glycoprotein, carcinoma orosomucoid-related antigen, (CORA), which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characteried by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.Type: GrantFiled: March 4, 1988Date of Patent: April 3, 1990Assignee: New England Deaconess Hospital CorporationInventors: Carol A. Toth, Peter Thomas